

Index

a

aliphatic poly(alkylene dicarboxylate)
polyesters (APDs) 73

aliphatic polyesters

- acronyms and chemical structures 8
- hydrophilicity 7
- lipases 7
- poly(caprolactone), *see* poly(caprolactone) (PCL)
- poly(glycolic acid), *see* poly(glycolide)
- poly(lactic acid), *see* poly(lactic acid) (PLA)
- RROP, *see* radical ring-opening polymerization (RROP)

American Society for Testing and Materials (ASTM) 236

amorphous PLA 109

APDs, *see* aliphatic poly(alkylene dicarboxylate) polyesters (APDs)

Aramids 324

ART stent 383

atom transfer radical polymerization (ATRP) 31

b

bacterial polyhydroxyalkanoate granules

- amphiphilic proteins 64
- biofuels 58
- biogenesis 48, 49
- bioplastics 59
- biopolyester nanoparticles 61, 62
- biopolyesters 49–51
- budding model 54, 55
- cellular robustness 64
- drug delivery carrier 60
- fibers 59
- fine chemicals 60
- industrial production 56–58
- low production cost 63

- medical applications 64
- medical implant materials 59, 60
- micelle model 54
- non-covalently attached proteins 55
- packaging films 59
- polyester syntheses, *see* polyester syntheses
- spherical inclusions, *see* PHA inclusions
- surface proteins 61

bamboo/PLA composites 329

bare metal stents (BMSs) 300

bioactive molecules 170, 172, 179

biodegradability 235, 322

biodegradable polyesters blends 325, 326

biodegradable stents 302

- balloon expansion 302, 303
- creep 303, 304
- engineering solutions *vs.* clinical implications 305
- fatigue failure 304
- magnesium 307
- material degradation 304
- material requirements 305, 306
- polymers 308
- selection of 307

Biomax® Strong 253

biopolymers, classification of 235, 236

block PHAs 63

BMSs, *see* bare metal stents (BMSs)

budding model 54, 55

c

CAD/CAM technologies 218

carbon fiber reinforced PLA composites 326

carbon fiber reinforced polymer (CFRP) composites 323, 326

cellulosic fiber reinforced composites 329

chain-growth polymerization 1

- chicken feather fibers (CFF)/PLA composites 329
- chitosan(CS)/PCL vascular scaffolds 174
- CKAs, *see* cyclic ketene acetals (CKAs)
- coated metal stents (CMSs) 301
- coaxial electrospun drug/biopolymer nanofibers 286
 - core-shell structured fibers 284, 285
 - porous core/sheath structured composite nanofibers 285
 - PVP/zein 283
- coconut fibers/PLA 329
- co-electrospinning 174
- cold-crystallization 116–118
- collagen 173
- compostability 235
- condensation polymerization 1, 5
- conetworks 145, 146
- controlled radical polymerization 31
- cotton fibers/PLA composites 328
- craze morphology 245
- cumulative drug release rate 196
- cyclic ketene acetals (CKAs) 26, 27
 - controlled radical polymerization 31
 - synthetic scheme 26
 - unsaturated polyesters 30
- cyclophosphamide-loaded gliadin nanoparticles 290

- d**
- debonded morphology 247
- Degussa method 76
- DESs, *see* drug-eluting stents (DESs)
- Diels-Alder reactions 137, 138, 141
- D-lactic acid 110
- 3-D nanoporous nanofibrillar network 225, 227, 232
- drug-eluting stents (DESs) 301
- drug-loaded biopolymer nanofibers
 - multi-component 279, 280
 - nanoparticles 280–283
 - single-component 277–279

- e**
- E-glass fiber reinforced composites 324, 327
- EAC, *see* ethylene/acrylate copolymer (EAC)
- EBA-GMA, *see* ethylene/n-butyl acrylate/glycidyl methacrylate terpolymer (EBA-GMA)
- electro-active SMPs 135
- electroresponsive SMPs 144
- electrospinning 191–194, 198, 201, 203, 206, 221, 275, 292
 - experimental setup 276
 - electrospinning-electrospraying 174
 - electrospun drug/biopolymer nanofibers 289–292
 - electrospinning 175
 - electrospun PLA: PCL fiber mats
 - apparatus setup 194
 - biodegradability 207, 208
 - blend ratio 198, 202
 - co-solvents 193, 200, 201
 - drug delivery 191
 - DSC data 196, 203, 204
 - FTIR spectra 197, 205
 - material formulations 195
 - nanofibre diameters 200, 201
 - SEM micrographs 199, 202
 - solution viscosity 196, 197, 200, 201
 - tetracycline hydrochloride (TCH) drug release rate 197, 206
 - XRD analysis 196, 202, 203
 - electrospun polyester scaffolds
 - bioactive molecules 170–172, 179
 - biocompatibility improvement, *see* surface functionalization
 - biodegradable polyesters, preparation of 156, 157, 159
 - co-electrospinning 174
 - electrospinning-electrospraying 174, 175
 - gelatin/PGA blend 173
 - hydroxyapatite 173
 - plasma treatment 162, 164, 165
 - PLCL/collagen nanofibers 173
 - pretreatments 172–175
 - production techniques 156
 - spirulina 173
 - surface functionalization, *see* surface functionalization
 - tissue engineering 155, 176, 177
 - UV radiation 167, 170
 - UV-ozone (UV/O₃) treatment 165–167
 - wet chemical surface modification 160, 162
 - emulsification 218
 - emulsion electrospinning 178
 - emulsion electrospun drug/biopolymer nanofibers 287
 - BSA molecules 287
 - core-shell structures 286
 - doxorubicin hydrochloride (DOX) 286
 - hydroxycamptothecin (HCPT) 287
 - pDNA polyplexes 289
 - polymeric drug carriers 286
 - enzyme-assisted photolithography (EAPL) 168
 - epoxy (EP) -PCL conetworks 146

- esterification reaction kinetic modeling
- Flory's self-catalyzed reaction model 87
 - functional group approach, 87, 88, *see also* functional group models
 - modeling approaches 88
 - molecular species models 88
 - overall reaction model 88, 97
 - silica nanoparticles effect 98–100
- ethylene/acrylate copolymer (EAC) 252
- ethylene-co-vinyl acetate (EVA) 251
- f**
- falling weight testing 244
- fiber reinforced polymer (FRP) composites
- aim 323
 - glass/carbon materials 323
 - natural fibers 324
 - synthetic fibers 324, 325
 - types 323
- fibronectin 170
- flax/PHB/HV composites 328
- Flory's self-catalyzed reaction model 87
- freeze-drying 218
- full IPN structured thermosets 148
- functional biodegradable polyesters
- alkyne groups 34
 - controlled radical polymerization 31
 - gene transfection agents 35
 - hydroxyl groups 33, 34
 - ionomers, compostability of 35, 36
 - radical initiated double ring-opening polymerization 30
 - self-assembling polymeric micelles 37–39
 - semicrystalline and amorphous PCL 39, 40
 - thermoresponsive polymers 35, 37
- functional group models 87, 88
- acid end groups, fractional conversion of 95–97
 - catalyst molar ratio, effects of 92, 94
 - kinetic rate constants 92, 93
 - mathematical model, development of 90, 91
 - mole number *vs.* esterification time 94, 95
 - normalized weight fraction *vs.* esterification time 94, 95
 - number average degree of polymerization *vs.* esterification time 91, 94–96
 - reaction mechanism 88–90
- g**
- gas foaming 218
- gelatin 173
- global biodegradable plastics market 74
- h**
- heparin 172
- hydrogel matrix-entrapped PLGA-paclitaxel microspheres 290
- hydroxyapatite (HA) 173
- i**
- impact testing 244
- interpenetrating networks (IPNs) 148
- j**
- jute/PLA composites 327
- k**
- kenaf fibers/PLA composites 328
- Kevlar 324
- l**
- lactic acid 110
- lactide 110
- laminin 170
- linear, cyano-functionalized polynorbornene 139
- L-lactic acid 110
- m**
- macromolecules 2
- magnetically active SMPs 135, 140
- melt-blending, *see* rubber-toughened polylactide
- melt-crystallization 116–118
- melt polycondensation 79
- 2-methylene-1,3-dioxepane (MDO) 26, 28, 30
- MFC, *see* microfibrils reinforced composites (MFC)
- micelle model 54
- micro-fibrillar composites (MFCs)
- advantages 309
 - characteristic feature 220
 - key requirements 219
 - manufacturing equipment 219
 - manufacturing process 309
 - PET 221, 222
 - PGA 221
 - PLA 223
 - PLLA/PGA, *see* PLLA/PGA nano-/microfibrillar polymer-polymer composites
 - process steps 219
- molecular species models 88
- multi-shape SMPs 132

n

- nanofiber self-assembly 218
- nanofibrillar composites (NFCs) 220
- nanofibrillar single polymer composites (SPCs) 221
- nanoparticles-mediated compatibilization process
 - cellulose nanocrystals 260
 - vs. copolymer-based compatibilizers 258
 - *in situ* generated compatibilizers 257
 - montmorillonite clay nanocomposites 260, 261
 - organoclays 258, 259
 - silica nanocomposites 259
- nano-sized polymers
 - biomedical application 229, 231
 - cold drawing 227
 - hydrogen bonding 223–225, 227
 - mechanism of formation 227–229
- natural fiber reinforced composites 327
- natural rubber 2
- Nomex 324
- nylon 4
- nylon 6 4
- nylon 6,6 4

o

- one-way SMPs 132, 133, 136
- overall reaction model 88, 97

p

- particulate leaching 218
- PCL, *see* poly(caprolactone) (PCL)
- PCL/PHB composites 330
- PCL/PLA blends 325
- PCL/PVA co-electrospinning scaffolds 174
- PDLA, *see* poly(D-lactic acid) (PDLA)
- PEBA, *see* poly(ethylene oxide-*b*-amide-12) (PEBA)
- peroxide crosslinked poly(propylene sebacate) 137
- PET microfibrils 221, 222
- petroleum-based commodity thermoplastics 241
- PHA inclusions
 - bioseparations 65
 - diagnostics and imaging 66
 - drug delivery 65
 - immobilised enzymes 66
 - protein purification 65
 - self-assembly 53
 - vaccine delivery 66
- PHB synthase 48, 52
- PHBHHx 56, 59, 60
- phosphate glass (PG) reinforced PLA composites 326, 327
- photocurable, biodegradable multiblock SMPs 140
- PLA, *see* poly(lactic acid) (PLA)
- PLA/hemp hybrid yarn composites 328
- PLA/natural rubber composites 330
- PLA/PBS composites 330
- PLA/PHB composites 330
- PLA/polyhedral oligomeric silsesquioxane (POSS) composites 330
- PLA/polyurethane (PU) composites 331
- plasma modification techniques
 - advantages 162
 - disadvantages 162, 163
 - hot and cold plasmas 164
 - oxygen plasma treatment 164
 - processes 163
- PLLA, *see* poly(L-lactic acid) (PLLA)
- PLLA/PDLA stereocomplex crystals 123, 124
- PLLA/PGA nano-/microfibrillar polymer-polymer composites
 - creep resistance 316, 317
 - mechanical properties 314
 - MFC film molding 310–312
 - preparation 310
 - scanning electron microscope images 312, 313
 - storage and loss moduli 315, 316
 - stress relaxation curves 315
- poly((R)-3-hydroxybutyrate-co-(R)-3-hydroxyvalerate) (PHBV) 56, 60
- poly(3-hydroxybutyrate) (PHB) 47, 63
 - biobeads 65, 66
 - biosynthesis genes 48
 - drug delivery carrier 60
 - fibers 59
 - industrial production 56, 58
- poly(butylene terephthalate) (PBT) 74
- poly(caprolactone) (PCL)
 - applications 18
 - chemical and physical properties 17
 - Polyurethane, manufacture of 15, 16
 - ring-opening polymerization 15–17
- poly(D,L-lactide) (PDLLA) 10
- poly(D-lactic acid) (PDLA)
 - stereocomplex crystals 124
- poly(ethylene oxide-*b*-amide-12) (PEBA) 252
- poly(ethylene terephthalate) (PET) 74, 75
- poly(glycolic acid) (PGA) 7, 12, 13
- poly(glycolide)
 - absorbable sutures 14
 - applications 14, 15
 - drug delivery system 14

- intramolecular ester interchange mechanism 13
- ring-opening polymerization 12, 13
- surgery implantation 14, 15
- thermal and mechanical properties 13, 14
- poly(lactic acid) (PLA) 192
 - advantages 109
 - α/α' crystals 111
 - 6-membered cyclic esters 9
 - applications 11, 12
 - biomedical applications 109
 - chemical and physical properties 10, 11
 - cold-crystallization vs. melt-crystallization 116–118
 - composites 334
 - crystallization rates, molar mass influence 120, 121
 - crystal polymorphism 111
 - DSC data 203
 - elongation at break 112, 113
 - food-packaging 12
 - half-time of crystallization 119
 - isothermal bulk crystallization rates 119–121
 - limitations 109, 125
 - microbial synthesis 64, 65
 - microfibrils 223
 - non-isothermal bulk crystallization rates 120, 121
 - nucleation rate 114
 - onset time of crystal nuclei formation vs. temperature 115, 117
 - plasticizers effect 117, 119
 - polarizing optical microscopy (POM) images 114, 116, 118
 - publication trend 6
 - ring-opening polymerization 9, 10
 - 6-membered cyclic esters 9
 - spherulite density vs. crystallization temperature 114
 - spherulite growth rates, D-lactic acid content influence 122, 123
 - stereocomplex crystals 123, 124
 - synthetic routes 110
 - thermal analysis data 10
 - three-phase structure 112–114
 - water vapor permeability 112, 113
 - WAXS patterns 112
 - XRD analysis 203
 - Young's modulus 112, 113
- poly(L-lactic acid) (PLLA)
 - onset time of crystal nuclei formation vs. temperature 117
 - stereocomplex crystals 124
- poly(L-lactide) (PLA) 74
- poly(L-lactide-co-D,L-lactide) (PLDLLA) 10
- poly(L-lactide-co- ϵ -caprolactone)s (PLACLs) 138
- Poly(MDO-co-MMA-co-DMAEMA.BrC₂H₅) 36
- poly(NIPAAm-co-BMDO) 37
- poly(PEG-*b*-(BMDO-co-DMAEMA)) 36
- poly(propylene alkylanedicarboxylate) polyesters
 - applications 80
 - cold crystallization temperatures 81
 - crystallization half-times 82
 - DSC traces 81
 - enzymatic hydrolysis 83–85
 - equilibrium melting points 81
 - esterification modeling, *see* esterification reaction kinetic modeling
 - glass transition temperature 81
 - melt polycondensation method 79
 - melting points 80
 - polycondensation modeling, *see* polycondensation reaction kinetic modeling
 - step reaction kinetic modeling 85–87
 - synthesis methods 78
- poly(propylene succinate) (PPSu)
 - esterification kinetics, *see* esterification reaction kinetic modeling
 - polycondensation kinetics, *see* polycondensation reaction kinetic modeling
- poly(propylene terephthalate) (PPT) 75
- poly(R,S-3-hydroxybutyrate) (a-PHB) 330
- poly(trimethylene carbonate) (PTMC) 139
- poly(trimethylene carbonate-co-D,L-lactide) random copolymers 139
- poly(ϵ -caprolactone) (PCL) 192
 - DSC data 203
 - XRD analysis 203
- poly[(3-hydroxybutyrate)-co-(3-hydroxyvalerate)] (PHBV) 139
- polybenzoxazine-PU conetworks 146
- polycaprolactone (PCL) 74
- polycondensation reaction kinetic modeling
 - end group analysis 103, 104
 - intrinsic viscosity vs. time 102, 103
 - kinetic rate constants 103, 105
 - mathematical model, development of 101, 102
 - reaction scheme 100, 101
 - theoretical simulation curves 102–104
- poly-D,L-lactide (PDLLA) 10
- poly-D-lactide (PDLA) 10, 11

- polyester syntheses
 - catalytic reaction mechanism 52, 53
 - classes of 47
 - genome sequences 51
 - primary structures 51
 - secondary structures 52
 - polyester-based biodegradable composites
 - biomedical applications 332, 333
 - commodity applications 334
 - polyethylene terephthalate (PET) 5
 - chemical structure 5
 - publication trend 6
 - polyhydroxyalkanoates (PHAs), 74 *see also*
 - bacterial polyhydroxyalkanoate granules
 - polylactide (PLA)
 - applications 237
 - Biomax[®] Strong 253
 - cavitation mechanism 246, 247
 - commercial impact modifiers 253, 254
 - crazing mechanism 245
 - crystal forms 240
 - crystallinity extent 243
 - debonding mechanism 247
 - drawbacks 241
 - glass transition temperatures 240, 241
 - global production capacity 237
 - impact modifiers, 243, *see also*
 - rubber-toughened polylactide
 - impact resistance testing methods 244
 - lactic acid 237
 - lactone ROP, coordination-insertion
 - mechanism of 239, 240
 - mechanical properties 241
 - melting temperatures 240, 241
 - *vs.* petroleum-based commodity
 - thermoplastics 241
 - plasticizers 243
 - polycondensation method 238, 239
 - polymer blending 242
 - ROP 238, 239
 - rubber-toughening, *see* rubber-toughened
 - polylactide
 - shear-yielding mechanism 246
 - Sn(oct)₂-catalyzed ROP 239
 - stereochemical structure 240
 - poly-L-lactide (PLLA) 10, 11
 - polymer composites
 - biodegradability costs 322
 - degradation 321
 - medical applications 322
 - polymeric ethyl oxalates 5
 - polyurethane (PU)/poly(ethylene glycol)
 - methacrylate (PEGMA) cross-linked
 - hybrid scaffolds 170
 - polyurethane (PU)-based SMPs 142, 143
 - polyurethanes 15, 16
 - 1,3-propanediol (1,3-PD)
 - applications 75
 - Degussa method 76
 - engine coolant formulations 75
 - glycerol synthetic route 76, 77
 - microbial production 77, 78
 - properties 75
 - Shell method 76
 - PVA/PETG model system 228, 229
- r**
- radical initiated double ring-opening
 - polymerization 30
 - radical ring-opening polymerization (RROP)
 - back-biting H-transfer reactions 29
 - CKAs, *see* cyclic ketene acetals (CKAs)
 - functional polyesters, *see* functional
 - biodegradable polyesters
 - hydroxyl functionalized polyesters 33, 34
 - reaction mechanism 28–30
 - unsaturated polyesters 30
 - renewability 236
 - renewable polymers 236, 237
 - reversible addition fragmentation transfer
 - (RAFT) polymerization 31
 - ring-opening polymerization (ROP) 25, 238
 - PCL 15–17
 - PLA 9, 10
 - poly(glycolide) 12, 13
 - RROP, *see* radical ring-opening polymerization
 - (RROP)
 - rubber cavitation 246, 247
 - rubber-toughened polylactide
 - annealing 263, 264, 266
 - crystallization, nucleating agent for
 - 265–267
 - EAC 252
 - EBA-GMA 251, 252
 - EVA 251
 - impact fractured surfaces, morphologies of
 - 265, 267
 - interpenetrating networks 262, 263
 - nanoparticles, *see* nanoparticles-mediated
 - compatibilization process
 - particle size 268
 - PCL-based additives 248–250
 - PEBA 252
 - polyurethane elastomer blend 250
- 5**
- self-reinforced poly(L-lactide) rods 11
 - semi crystalline PLA 240, 241

semi interpenetrating network 146, 147
 semi-interpenetrating PU-PLA network
 262
 semi IPN structured EP/PCL 147
 shape fixity ratio (R_f) 132, 134
 shape memory polymers (SMPs)
 – applications 131, 148, 149
 – benefits 149
 – cross-linked copolymers 140, 142
 – disadvantages 149
 – homopolymers 134
 – linear copolymers 138, 139
 – peroxide crosslinked PCL 135, 137
 – peroxide crosslinked poly(propylene
 sebacate) 137
 – photo crosslinked PCL 135, 140
 – photosets PCL 135
 – PLA 134
 – PLA/PCL blends 144
 – PLA/PEG crosslinked blends 145
 – PLA/thermoplastic PU blends 144
 – plasticized PLA 134
 – polyurethane (PU) systems 142, 143
 – PU/PCL blend 145
 – radiation crosslinked PCL 135
 – self healing 149
 – slow crystallizing polymers 134
 – sol-gel crosslinked PCL 135, 136
 – stents 148, 149
 – sutures 148
 – thermoreversible crosslinks 137, 138
 – thermosets, *see* thermosetting SMPs
 shape recovery ratio (R_r) 132, 134
 shear bands morphology 246
 Shell method 76
 single-step SM programming procedure 141
 sisal fibers/PLA composites 328
 SMPs, *see* shape memory polymers (SMPs)
 solvent casting 218, 325
 spirulina 173
 Staudinger's macromolecular concept 1, 3
 stenting 299
 surface functionalization
 – bioactive molecules 170, 172
 – plasma treatment 162–165
 – UV radiation 167, 169, 170
 – UV-ozone (UV/O₃) treatment 165–167
 – wet chemical methods 160, 162
 surface-initiated atom transfer radical
 polymerization (SI-ATRP) method 169

t

tensile testing 244
 TERM field 215
 terylene, *see* polyethylene terephthalate (PET)
 textile technologies 218
 thermally induced phase separation 218
 thermoresponsive biodegradable polymers
 35, 37
 thermoresponsive SMPs 139
 thermoreversible crosslinked SMPs 137, 138
 thermosetting SMPs
 – conetworks 145, 146
 – IPNs 148
 – semi IPNs 146, 147
 tissue engineering scaffolds
 – basic requirements 218
 – biodegradability 217
 – formation techniques 218, 219
 – MFC, *see* microfibrils reinforced composites
 (MFC)
 – purposes 216
 – working principle 216, 217
 tissue substitutes, need for 215, 216
 triple-shape memory polymers 140
 two-step SM programming methods 141
 two-way SMPs 132, 136, 137

u

Uniquely-encapsulated drug/biopolymer
 nanofiber systems
 – coaxial electrospinning, *see* coaxial
 electrospun drug/biopolymer nanofibers
 – electrospinning, *see* electrospun
 drug/biopolymer nanofibers
 – emulsion electrospinning, *see* emulsion
 electrospun drug/biopolymer nanofibers
 unsaturated polyesters (USPs) 30
 UV-ozone (UV/O₃) surface treatment
 – cross-linked collagen scaffolds 166
 – *vs.* plasma methods 165, 166

v

vetiver grass fibers/PLA 329
 video-controlled mechanical testing 244

w

wet chemical surface modification 160, 162

